Oncternal Therapeutics Beheer
Beheer criteriumcontroles 3/4
De CEO Oncternal Therapeutics is Jim Breitmeyer, benoemd in Jun2019, heeft een ambtstermijn van 5.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.62M, bestaande uit 37.5% salaris en 62.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.11% van de aandelen van het bedrijf, ter waarde $ 38.03K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 5.4 jaar.
Belangrijke informatie
Jim Breitmeyer
Algemeen directeur
US$1.6m
Totale compensatie
| Percentage CEO-salaris | 37.5% |
| Dienstverband CEO | 5.4yrs |
| Eigendom CEO | 1.1% |
| Management gemiddelde ambtstermijn | 3.8yrs |
| Gemiddelde ambtstermijn bestuur | 5.4yrs |
Recente managementupdates
Recent updates
We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation
Jun 14
Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?
Mar 03Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Nov 06Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely
Jul 12We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Jan 12FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy
Oct 03Oncternal Therapeutics begins phase 3 study of zilovertamab
Sep 27Oncternal Therapeutics: Selling For Under Cash Value
Sep 02Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M
Aug 09Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Aug 07Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study
Jul 14Oncternal Therapeutics: As Phase 2 Study Matures, Data Continues To Improve
Jun 07We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Apr 12Oncternal Therapeutics: Trading Near Cash With Impressive Results
Jan 04Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans
Nov 09Oncternal Therapeutics: Keep An Eye On This Biopharmaceutical Company
Oct 10Oncternal: Solid Data In 2 Cancers With High Unmet Need
Jun 17We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth
May 05Should Oncternal Therapeutics (NASDAQ:ONCT) Be Disappointed With Their 81% Profit?
Mar 01Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$35m |
| Jun 30 2024 | n/a | n/a | -US$36m |
| Mar 31 2024 | n/a | n/a | -US$36m |
| Dec 31 2023 | US$2m | US$609k | -US$39m |
| Sep 30 2023 | n/a | n/a | -US$42m |
| Jun 30 2023 | n/a | n/a | -US$43m |
| Mar 31 2023 | n/a | n/a | -US$46m |
| Dec 31 2022 | US$2m | US$580k | -US$44m |
| Sep 30 2022 | n/a | n/a | -US$41m |
| Jun 30 2022 | n/a | n/a | -US$39m |
| Mar 31 2022 | n/a | n/a | -US$35m |
| Dec 31 2021 | US$5m | US$557k | -US$31m |
| Sep 30 2021 | n/a | n/a | -US$26m |
| Jun 30 2021 | n/a | n/a | -US$21m |
| Mar 31 2021 | n/a | n/a | -US$18m |
| Dec 31 2020 | US$780k | US$530k | -US$17m |
| Sep 30 2020 | n/a | n/a | -US$19m |
| Jun 30 2020 | n/a | n/a | -US$19m |
| Mar 31 2020 | n/a | n/a | -US$37m |
| Dec 31 2019 | US$1m | US$502k | -US$34m |
| Sep 30 2019 | n/a | n/a | -US$31m |
| Jun 30 2019 | n/a | n/a | -US$28m |
| Mar 31 2019 | n/a | n/a | -US$7m |
| Dec 31 2018 | US$518k | US$426k | -US$7m |
Compensatie versus markt: De totale vergoeding ($USD 1.62M ) Jim } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 650.80K ).
Compensatie versus inkomsten: De vergoeding van Jim is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Jim Breitmeyer (70 yo)
5.4yrs
Tenure
US$1,623,074
Compensatie
Dr. James B. Breitmeyer, also known as Jim, M.D., Ph D., served as Director of Otonomy, Inc. since June 20, 2018 until February 2023. He serves as Director of Rebalance Health, Inc. He serves as the Chief...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 5.4yrs | US$1.62m | 1.11% $ 38.0k | |
| CFO & Treasurer | 5.4yrs | US$847.91k | 0.25% $ 8.5k | |
| Chief Technical & Scientific Officer | 3.8yrs | geen gegevens | 0.074% $ 2.6k | |
| General Counsel & Secretary | 3.6yrs | geen gegevens | 0.14% $ 4.9k | |
| Senior Vice President of Corporate Development | 3.3yrs | geen gegevens | geen gegevens |
3.8yrs
Gemiddelde duur
55.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ONCT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 5.4yrs | US$1.62m | 1.11% $ 38.0k | |
| Independent Director | 18.5yrs | US$59.80k | 0.12% $ 4.2k | |
| Independent Director | 5.4yrs | US$67.50k | 0.017% $ 579.9 | |
| Independent Director | 5.4yrs | US$67.00k | 0.044% $ 1.5k | |
| Independent Chairman of the Board | 5.4yrs | US$103.82k | 0.024% $ 828.1 | |
| Independent Director | 3.8yrs | US$61.32k | 0.00017% $ 5.8 | |
| Scientific Advisor | no data | geen gegevens | geen gegevens | |
| Independent Director | 5.4yrs | US$59.00k | 0.025% $ 850.4 | |
| Non-Independent Director | 5.4yrs | US$55.00k | 0.34% $ 11.6k | |
| Cell Therapy Scientific Advisory Board Member | 3yrs | geen gegevens | geen gegevens | |
| Prostate Cancer & Cell Therapy Scientific Advisory Board Member | 1.8yrs | US$941.21k | 0.062% $ 2.1k | |
| Cell Therapy Scientific Advisory Board Member | 3yrs | geen gegevens | geen gegevens |
5.4yrs
Gemiddelde duur
70yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ONCT wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.4 jaar).